ClinicalTrials.gg
CompletedNCT02607306DUAL™ I JapanUpdated Apr 9, 2021Results posted

A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide, Insulin Degludec and Liraglutide in Japanese Subjects With Type 2 Diabetes Mellitus.

A Phase 3 interventional study of insulin degludec/liraglutide and insulin degludec in Diabetes and Diabetes Mellitus, Type 2, sponsored by Novo Nordisk A/S. Completed at 76 sites in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2021-04-09.

Primary conditionDiabetes Mellitus, Type 2Registry: Diabetes MellitusReclassifiedWhy we changed it
Registry
Diabetes Mellitus — the first condition term the registry derived for this study.
ClinicalTrials.gg
Diabetes Mellitus, Type 2
Why
  1. The study's listed conditions name Diabetes Mellitus, Type 2, a narrower term within Diabetes Mellitus.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Novo Nordisk A/S · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
819
Allocation
Randomized
Ages
20 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 70 studies testing insulin degludec in Diabetes Mellitus, Type 2 — 4 open to participants now, 4 under way, 2 of them phase 3. insulin degludec · Diabetes Mellitus, Type 2.

Enrollment
7th of 70
819 · median 384
Started
2015
with 1 other
Phase 3
49 of 70
2 open now
Registered
45th of 70
by date
Lead sponsor
56 of 70
Novo Nordisk A/S

Among the 70 studies testing insulin degludec in Diabetes Mellitus, Type 2, this one is the 7th largest by enrollment, is one of 2 that started in 2015, is one of 49 in phase 3, and was the 45th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

4 of the 70 studies testing insulin degludec in Diabetes Mellitus, Type 2 are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About insulin degludec

insulin degludec: first FDA approval 2015 (RYZODEG 70/30), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 883 Diabetes Mellitus, Type 2 studies recruiting now, 374 (42%) set no upper age limit and 383 (43%) stop at 75 or younger; 52 take children under 18; 205 take healthy volunteers.

This study: 20 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 70 studies testing insulin degludec in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

This trial is conducted in Asia. The aim of this trial is to compare the efficacy and safety of insulin degludec/liraglutide, insulin degludec and liraglutide in Japanese subjects with type 2 diabetes mellitus.

03

Conditions studied

  • Diabetes
  • Diabetes Mellitus, Type 2

Browse trials for

04

In context

Diabetes Mellitus, Type 2 Reclassified

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

This study's enrollment of 819 is above the median of 80 across 8,359 interventional studies indexed under Diabetes Mellitus, Type 2.

Browse Diabetes Mellitus, Type 2 studies →

Lead sponsor

Novo Nordisk A/S is the lead sponsor of 1,408 studies on the registry; 105 are open to participants now.

Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.

Compared within Diabetes Mellitus, Type 2, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Diabetes Mellitus. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female Japanese subjects, age at least 20 years at the time of signing
  • Type 2 diabetes subjects (diagnosed clinically) at least 6 months prior to screening
  • (glycosylated ) 7.0-11.0 % (both inclusive) by central laboratory analysis, with the aim of a median of 8.3%. When approximately 50% of the randomised subjects have a HbA1c above 8.3%, the remaining subjects randomised must have a HbA1c below or equal to 8.3%; or when approximately 50% of the randomised subjects have a HbA1c below or equal to 8.3%, the remaining subjects randomised must have a HbA1c above 8.3%
  • Body-mass index () above or equal to 20 kg/m\^2
  • Subjects on stable therapy with one OAD (defined as unchanged medication and unchanged dose) for at least 60 days (metformin, a-GI, TZD, SU, SGLT2i or glinide) prior to screening according to approved Japanese labelling

Exclusion criteria

Exclusion Criteria:

  • Previous treatment with insulin (except for short-term treatment in connection with intercurrent illness including gestational diabetes)
  • Treatment with any medication for the indication of diabetes or obesity other than stated in the inclusion criteria in a period of 60 days before screening
  • Anticipated initiation or change in concomitant medications in excess of 14 days known to affect weight or glucose metabolism
  • Impaired liver function, defined as (ALT) or aspartate aminotransferase (AST) equal to or above 2.5 times
  • Renal impairment estimated (eGFR) below 60mL/min/1.73m\^2 as per Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI)
  • Screening calcitonin equal to or above 50 ng/L
  • History of pancreatitis (acute or chronic)
  • Personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia type 2 (MEN 2)
  • Subjects presently classified as being in (NYHA) Class IV
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

06

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
819 participants (actual)

Study arms

  • Experimental
    Insulin degludec/liraglutide OD

    Drug: insulin degludec/liraglutide

  • Active comparator
    Insulin degludec OD

    Drug: insulin degludec

  • Active comparator
    Liraglutide OD

    Drug: liraglutide

Interventions

  • Druginsulin degludec/liraglutide

    Drug pages: Insulin degludec · Liraglutide

    Injected s.c. / subcutaneously (under the skin) once daily (OD) , in combination with pre-trial OAD (oral antidiabetic drug)kept in unchanged dose.

  • Injected s.c. / subcutaneously (under the skin) once daily (OD) , in combination with pre-trial OAD (oral antidiabetic drug)kept in unchanged dose.

  • Injected s.c. / subcutaneously (under the skin) once daily (OD) , in combination with pre-trial OAD (oral antidiabetic drug)kept in unchanged dose.

07

What researchers measure

Primary outcomes

  1. Change From Baseline in HbA1c (Glycosylated Haemoglobin) Tested for Non-inferiority of IDegLira vs IDeg and Superiority of IDegLira vs Lira

    Change from baseline (week 0) in HbA1c after 52 weeks of treatment was measured. Statistical analyses were performed to test the hypotheses: non-inferiority of IDegLira vs. IDeg and superiority of IDegLira vs. Liraglutide (Lira).

    Time frame: Week 0, Week 52

Secondary outcomes

  1. Change From Baseline in Body Weight (kg)

    Change from baseline (week 0) in body weight after 52 weeks of treatment.

    Time frame: Week 0, Week 52

  2. Number of Treatment Emergent Severe or Blood Glucose (BG) Confirmed Hypoglycaemic Episodes

    Treatment emergent hypoglycaemic episode is defined as an event that had onset date on or after the first day of trial product administration, and no later than 7 days after the last day on trial product. Severe or BG confirmed hypoglycaemic episodes were defined as episodes that were severe according to the American Diabetes Association (ADA) classification or BG confirmed by a plasma glucose value \< 3.1 mmol/L (56 mg/dL) with or without symptoms consistent with hypoglycaemia. Severe hypoglycaemia according to the ADA definition: an episode requiring assistance of another person to actively administer carbohydrate, glucagon, or take other corrective actions. Plasma glucose concentrations may not be available during an event, but neurological recovery following the return of plasma glucose to normal is considered sufficient evidence that the event was induced by a low plasma glucose concentration.

    Time frame: Weeks 0-52

  3. Change From Baseline in HbA1c (Glycosylated Haemoglobin) Tested for Superiority of IDegLira vs IDeg

    Change from baseline (week 0) in HbA1c after 52 weeks of treatment was measured. Statistical analysis was performed to test the hypothesis: superiority of IDegLira vs. IDeg.

    Time frame: Week 0, Week 52

  4. Change From Baseline in Fasting Plasma Glucose (FPG)

    Change from baseline (week 0) in FPG after 52 weeks

    Time frame: Week 0, Week 52

  5. Insulin Dose

    Actual daily total insulin dose after 52 weeks of treatment.

    Time frame: After 52 weeks of treatment

  6. Responder (Yes/no): HbA1c Less Than 7.0%

    Number of subjects with HbA1c less than 7.0% after 52 weeks of treatment.

    Time frame: After 52 weeks of treatment

  7. Responder (Yes/no): HbA1c Less Than 7.0% and Change in Body Weight From Baseline Below or Equal to Zero

    Number of subjects with HbA1c less than 7.0% and without weight gain after 52 weeks of treatment.

    Time frame: After 52 weeks of treatment

  8. Responder (Yes/no): HbA1c Less Than 7.0% Without Treatment Emergent Severe or Blood Glucose (BG) Confirmed Symptomatic Hypoglycaemic Episodes During the Last 12 Weeks of Treatment.

    Number of subjects with HbA1c less than 7.0% after 52 weeks, who did not experience treatment emergent severe or BG confirmed symptomatic hypoglycaemic episodes during the last 12 weeks of treatment. Treatment emergent hypoglycaemic episode is defined as an event that had onset date on or after the first day of trial product administration, and no later than 7 days after the last day on trial product. Severe or BG confirmed symptomatic hypoglycaemic episodes were defined as episodes that were severe according to the ADA classification or BG confirmed by a plasma glucose value \< 3.1 mmol/L (56 mg/dL) with symptoms consistent with hypoglycaemia.

    Time frame: After 52 weeks of treatment

  9. Responder (Yes/no): HbA1c Less Than 7.0% and Change in Body Weight From Baseline Below or Equal to Zero and Without Treatment Emergent Severe or BG Confirmed Symptomatic Hypoglycaemic Episodes During the Last 12 Weeks of Treatment

    Number of subjects with HbA1c less than 7.0% and without weight gain, who did not experience treatment emergent severe or BG confirmed symptomatic hypoglycaemic episodes during the last 12 weeks of treatment. Treatment emergent hypoglycaemic episode is defined as an event that had onset date on or after the first day of trial product administration, and no later than 7 days after the last day on trial product. Severe or BG confirmed symptomatic hypoglycaemic episodes were defined as episodes that were severe according to the ADA classification or BG confirmed by a plasma glucose value \< 3.1 mmol/L (56 mg/dL) with symptoms consistent with hypoglycaemia.

    Time frame: After 52 weeks of treatment

  10. Responder (Yes/no): HbA1c Less Than 6.5%

    Number of subjects with HbA1c less than 6.5% after 52 weeks of treatment.

    Time frame: After 52 weeks of treatment

  11. Responder (Yes/no): HbA1c Less Than 6.5% and Change in Body Weight From Baseline Below or Equal to Zero

    Number of subjects with HbA1c less than 6.5% and without weight gain after 52 weeks of treatment.

    Time frame: After 52 weeks of treatment

  12. Responder (Yes/no): HbA1c Less Than 6.5% Without Treatment Emergent Severe or Blood Glucose (BG) Confirmed Symptomatic Hypoglycaemic Episodes During the Last 12 Weeks of Treatment.

    Number of subjects with HbA1c less than 6.5% after 52 weeks, who did not experience treatment emergent severe or BG confirmed symptomatic hypoglycaemic episodes during the last 12 weeks of treatment. Treatment emergent hypoglycaemic episode is defined as an event that had onset date on or after the first day of trial product administration, and no later than 7 days after the last day on trial product. Severe or BG confirmed symptomatic hypoglycaemic episodes were defined as episodes that were severe according to the ADA classification or BG confirmed by a plasma glucose value \< 3.1 mmol/L (56 mg/dL) with symptoms consistent with hypoglycaemia.

    Time frame: After 52 weeks of treatment

  13. Responder (Yes/no): HbA1c Less Than 6.5% and Change in Body Weight From Baseline Below or Equal to Zero and Without Treatment Emergent Severe or BG Confirmed Symptomatic Hypoglycaemic Episodes During the Last 12 Weeks of Treatment

    Number of subjects with HbA1c less than 6.5% with no weight gain, who did not experience treatment emergent severe or BG confirmed symptomatic hypoglycaemic episodes during the last 12 weeks of treatment. Treatment emergent hypoglycaemic episode is defined as an event that had onset date on or after the first day of trial product administration, and no later than 7 days after the last day on trial product. Severe or BG confirmed symptomatic hypoglycaemic episodes were defined as episodes that were severe according to the ADA classification or BG confirmed by a plasma glucose value \< 3.1 mmol/L (56 mg/dL) with symptoms consistent with hypoglycaemia.

    Time frame: After 52 weeks of treatment

  14. Change in Waist Circumference

    Change from baseline (week 0) in waist circumference after 52 weeks of treatment.

    Time frame: Week 0, Week 52

  15. Change in Blood Pressure (Systolic and Diastolic)

    Change from baseline in blood pressure (systolic and diastolic) after 52 weeks of treatment.

    Time frame: Week 0, Week 52

  16. Self-Measured Blood Glucose (SMBG) 9-point Profile: 9-point Profile (Individual Points in the Profile)

    Subjects were instructed to measure their plasma glucose at following timepoints: before breakfast, 90 minutes after start of breakfast, before lunch, 90 minutes after start of lunch, before dinner, 90 minutes after start of dinner, at bedtime, at 4:00 a.m. and before breakfast the following day.

    Time frame: After 52 weeks of the treatment

  17. Change in SMBG 9-point Profile - Mean of the 9-point Profile

    Subjects were instructed to measure their plasma glucose at following timepoints: before breakfast, 90 minutes after start of breakfast, before lunch, 90 minutes after start of lunch, before dinner, 90 minutes after start of dinner, at bedtime, at 4:00 a.m. and before breakfast the following day. Mean of the 9-point profile was defined as the area under the profile (calculated using the trapezoidal method) divided by the measurement time.

    Time frame: Week 0, week 52

  18. Change in SMBG 9-point Profile - Mean of Postprandial Increments (From Before Meal to 90 Min After for Breakfast, Lunch and Dinner)

    Subjects were instructed to measure their plasma glucose at following timepoints: before breakfast, 90 minutes after start of breakfast, before lunch, 90 minutes after start of lunch, before dinner, 90 minutes after start of dinner, at bedtime, at 4:00 a.m. and before breakfast the following day. The mean increment over all meals was derived as the mean of all available meal increments.

    Time frame: Week 0, week 52

  19. Total Cholesterol as a Ratio to Baseline at 52 Weeks

    Total cholesterol after 52 weeks of treatment was represented as ratio to baseline (week 0) values.

    Time frame: After 52 weeks of treatment

  20. Low Density Lipoprotein (LDL) Cholesterol as a Ratio to Baseline at 52 Weeks

    Low density lipoprotein (LDL) cholesterol after 52 weeks of treatment was represented as ratio to baseline (week 0) values.

    Time frame: After 52 weeks of treatment

  21. High Density Lipoprotein (HDL) Cholesterol as a Ratio to Baseline at 52 Weeks

    High density lipoprotein (HDL) cholesterol after 52 weeks of treatment was represented as ratio to baseline (week 0) values.

    Time frame: After 52 weeks of treatment

  22. Very Low Density Lipoprotein (VLDL) Cholesterol as a Ratio to Baseline at 52 Weeks

    Very low density lipoprotein (VLDL) cholesterol after 52 weeks of treatment was represented as ratio to baseline (week 0) values.

    Time frame: After 52 weeks of treatment

  23. Triglycerides as a Ratio to Baseline at 52 Weeks

    Triglycerides after 52 weeks of treatment was represented as ratio to baseline (week 0) values.

    Time frame: After 52 weeks of treatment

  24. Free Fatty Acids as a Ratio to Baseline at 52 Weeks

    Free fatty acids after 52 weeks of treatment was represented as ratio to baseline (week 0) values.

    Time frame: After 52 weeks of treatment

  25. Fasting C-peptide as a Ratio to Baseline at 52 Weeks

    Fasting C-peptide after 52 weeks of treatment was represented as ratio to baseline (week 0) values.

    Time frame: After 52 weeks of treatment

  26. Fasting Human Insulin as a Ratio to Baseline at 52 Weeks

    Fasting human insulin after 52 weeks of treatment was represented as ratio to baseline (week 0) values.

    Time frame: After 52 weeks of treatment

  27. Fasting Glucagon as a Ratio to Baseline at 52 Weeks

    Fasting glucagon after 52 weeks of treatment was represented as ratio to baseline (week 0) values.

    Time frame: After 52 weeks of treatment

  28. Proinsulin as a Ratio to Baseline at 52 Weeks

    Proinsulin after 52 weeks of treatment was represented as ratio to baseline (week 0) values.

    Time frame: After 52 weeks of treatment

  29. Number of Treatment Emergent Adverse Events (TEAEs)

    Treatment emergent adverse event is defined as an event that had onset date on or after the first day of trial product administration, and no later than 7 days after the last day on trial product. If the event had onset date before the first day of exposure on randomised treatment and increased in severity during the treatment period and until 7 days after the last drug date, then this event was considered as a TEAE.

    Time frame: 0-52 weeks

  30. Number of Treatment Emergent Severe or Blood Glucose (BG) Confirmed Symptomatic Hypoglycaemic Episodes

    Treatment emergent hypoglycaemic episode is defined as an event that had onset date on or after the first day of trial product administration, and no later than 7 days after the last day on trial product. Severe or BG confirmed symptomatic hypoglycaemic episodes were defined as episodes that were severe according to the American Diabetes Association (ADA) classification or BG confirmed by a plasma glucose value \< 3.1 mmol/L (56 mg/dL) with symptoms consistent with hypoglycaemia. Severe hypoglycaemia according to the ADA definition: an episode requiring assistance of another person to actively administer carbohydrate, glucagon, or take other corrective actions. Plasma glucose concentrations may not be available during an event, but neurological recovery following the return of plasma glucose to normal is considered sufficient evidence that the event was induced by a low plasma glucose concentration.

    Time frame: 0-52 weeks

  31. Number of Treatment Emergent Nocturnal Severe or BG Confirmed Symptomatic Hypoglycaemic Episodes

    Treatment emergent hypoglycaemic episode is defined as an event that had onset date on or after the first day of trial product administration, and no later than 7 days after the last day on trial product. Nocturnal period: The period between 00:01 and 05:59 a.m. (both inclusive). Severe or BG confirmed symptomatic hypoglycaemic episodes were defined as episodes that were severe according to the American Diabetes Association (ADA) classification or BG confirmed by a plasma glucose value \< 3.1 mmol/L (56 mg/dL) with symptoms consistent with hypoglycaemia. Severe hypoglycaemia according to the ADA definition: an episode requiring assistance of another person to actively administer carbohydrate, glucagon, or take other corrective actions. Plasma glucose concentrations may not be available during an event, but neurological recovery following the return of plasma glucose to normal is considered sufficient evidence that the event was induced by a low plasma glucose concentration.

    Time frame: 0-52 weeks

  32. Number of Treatment Emergent Hypoglycaemic Episodes According to American Diabetes Association (ADA) Definition

    Results represent total number of treatment emergent hypoglycaemic episodes that fall under ADA's definition of hypoglycaemia. ADA's definition of hypoglycaemia includes following categories: 1. Severe hypoglycaemia 2. Documented symptomatic hypoglycaemia 3. Asymptomatic hypoglycaemia 4. Probable symptomatic hypoglycaemia 5. Pseudo-hypoglycaemia. Treatment emergent hypoglycaemic episode is defined as an event that had onset date on or after the first day of trial product administration, and no later than 7 days after the last day on trial product.

    Time frame: 0-52 weeks

  33. Anti-drug Antibodies: Anti-insulin Degludec Antibodies

    Insulin degludec (IDeg)-specific antibodies were measured at week 52, as %B/T (percentage of bound \& precipitated radioactive drug/total added drug to the sample). A sample is measured in 2 different series. In series 1, the radioactive IDeg (tracer) and surplus unlabeled IDeg are added to the sample. In series 2, the tracer and surplus unlabeled human insulin are added to the sample. Series 1 represents unspecific background binding. Series 2 represents IDeg specific antibodies including unspecific background binding. The reported %B/T is calculated by subtracting the background %B/T in series 1 from the %B/T result in series 2. If the background result has higher values than the %B/T in series 2, the resulting value is negative %B/T. Here, a negative %B/T value means that the test samples do not have IDeg-specific antibodies. The reason for getting a negative value for %B/T is due to variation in the analytical background. Thus, the results presented are not a change from baseline.

    Time frame: at week 52

  34. Anti-drug Antibodies: Number of Participants Positive or Negative for Anti-liraglutide Antibodies

    Anti-liraglutide antibodies were measured at week 52. Number of participants positive or negative for anti-liraglutide antibodies at week 52 were reported.

    Time frame: at week 52

  35. Change in Clinical Evaluation: Fundoscopy or Fundus Photography

    The result of the fundus photography/dilated fundoscopy was interpreted by the investigator into following categories: Normal; Abnormal (Abn), Not Clinically significant (NCS); Abnormal, Clinically significant (CS). Reported results are number of subjects with 'normal'; 'Abn, NCS' and 'Abn, CS' fundoscopy/fundus photography results at screening (week -2 to week 0) and week 52.

    Time frame: at screening (week -2 to week 0), at week 52

  36. Change in Clinical Evaluation: Electrocardiogram (ECG)

    The result of the ECG was interpreted by the investigator into following categories: Normal; Abnormal (Abn), Not Clinically significant (NCS); Abnormal, Clinically significant (CS). Reported results are number of subjects with 'normal'; 'Abn, NCS' and 'Abn, CS' ECG results at screening (week -2 to week 0) and week 52.

    Time frame: at screening (week -2 to week 0), at week 52

  37. Change in Clinical Evaluation: Pulse

    Change in pulse after 52 weeks of treatment.

    Time frame: Week 0, week 52

  38. Serum Concentrations of Insulin Degludec

    Samples from the IDegLira and IDeg arms were analysed for serum concentrations of insulin degludec using validated ELISA assays.

    Time frame: Weeks 2, 8, 16, 26, 44, 52

  39. Plasma Concentrations of Liraglutide

    Samples from the IDegLira and liraglutide arms were assayed for plasma concentrations of liraglutide using validated ELISA assays.

    Time frame: Weeks 2, 8, 16, 26, 44, 52

08

Results

Posted Jul 29, 2019

Participant flow

The trial was conducted at 71 sites in Japan. 71 sites screened and randomised subjects.

Participant flow — Overall Study
MilestoneInsulin Degludec/LiraglutideInsulin DegludecLiraglutide
Started275271273
Completed254248263
Not completed212310
Withdrew: Adverse event866
Withdrew: Unclassified140
Withdrew: Withdrawal by subject8102
Withdrew: Lack of efficacy011
Withdrew: Protocol violation421

Outcome measures

PrimaryChange From Baseline in HbA1c (Glycosylated Haemoglobin) Tested for Non-inferiority of IDegLira vs IDeg and Superiority of IDegLira vs Lira

Change from baseline (week 0) in HbA1c after 52 weeks of treatment was measured. Statistical analyses were performed to test the hypotheses: non-inferiority of IDegLira vs. IDeg and superiority of IDegLira vs. Liraglutide (Lira).

Time frame:
Week 0, Week 52
Reported as:
Mean · Percentage of HbA1c
Change From Baseline in HbA1c (Glycosylated Haemoglobin) Tested for Non-inferiority of IDegLira vs IDeg and Superiority of IDegLira vs Lira
Percentage of HbA1cInsulin Degludec/LiraglutideInsulin DegludecLiraglutide
Change From Baseline in HbA1c (Glycosylated Haemoglobin) Tested for Non-inferiority of IDegLira vs IDeg and Superiority of IDegLira vs Lira-2.42 ± 1.04-1.80 ± 1.02-1.80 ± 0.92
Statistical analysis
  • Insulin Degludec/Liraglutide vs Insulin Degludec · ANCOVA · p = <0.0001 (p-value for non-inferiority of IDegLira vs IDeg is presented) · Treatment contrast: -0.63 · 95% CI -0.75 to -0.52
  • Insulin Degludec/Liraglutide vs Liraglutide · ANCOVA · p = <0.0001 (p-value for superiority of IDegLira vs Lira is presented) · Treatment contrast: -0.48 · 95% CI -0.60 to -0.37
SecondaryChange From Baseline in Body Weight (kg)

Change from baseline (week 0) in body weight after 52 weeks of treatment.

Time frame:
Week 0, Week 52
Reported as:
Mean · Kg
Change From Baseline in Body Weight (kg)
KgInsulin Degludec/LiraglutideInsulin DegludecLiraglutide
Change From Baseline in Body Weight (kg)2.9 ± 3.24.1 ± 4.3-1.0 ± 3.4
Statistical analysis
  • Insulin Degludec/Liraglutide vs Insulin Degludec · ANCOVA · p = 0.0001 (p-value for superiority of IDegLira vs IDeg is presented) · Treatment contrast: -1.19 · 95% CI -1.80 to -0.59
SecondaryNumber of Treatment Emergent Severe or Blood Glucose (BG) Confirmed Hypoglycaemic Episodes

Treatment emergent hypoglycaemic episode is defined as an event that had onset date on or after the first day of trial product administration, and no later than 7 days after the last day on trial product. Severe or BG confirmed hypoglycaemic episodes were defined as episodes that were severe according to the American Diabetes Association (ADA) classification or BG confirmed by a plasma glucose value \< 3.1 mmol/L (56 mg/dL) with or without symptoms consistent with hypoglycaemia. Severe hypoglycaemia according to the ADA definition: an episode requiring assistance of another person to actively administer carbohydrate, glucagon, or take other corrective actions. Plasma glucose concentrations may not be available during an event, but neurological recovery following the return of plasma glucose to normal is considered sufficient evidence that the event was induced by a low plasma glucose concentration.

Time frame:
Weeks 0-52
Reported as:
Number · Episodes
Number of Treatment Emergent Severe or Blood Glucose (BG) Confirmed Hypoglycaemic Episodes
EpisodesInsulin Degludec/LiraglutideInsulin DegludecLiraglutide
Number of Treatment Emergent Severe or Blood Glucose (BG) Confirmed Hypoglycaemic Episodes46786913
Statistical analysis
  • Insulin Degludec/Liraglutide vs Insulin Degludec · Negative binomial regression · p = <0.0001 (p-value for superiority of IDegLira vs IDeg is presented) · Treatment contrast: 0.48 · 95% CI 0.35 to 0.68
SecondaryChange From Baseline in HbA1c (Glycosylated Haemoglobin) Tested for Superiority of IDegLira vs IDeg

Change from baseline (week 0) in HbA1c after 52 weeks of treatment was measured. Statistical analysis was performed to test the hypothesis: superiority of IDegLira vs. IDeg.

Time frame:
Week 0, Week 52
Reported as:
Mean · Percentage of HbA1c
Change From Baseline in HbA1c (Glycosylated Haemoglobin) Tested for Superiority of IDegLira vs IDeg
Percentage of HbA1cInsulin Degludec/LiraglutideInsulin DegludecLiraglutide
Change From Baseline in HbA1c (Glycosylated Haemoglobin) Tested for Superiority of IDegLira vs IDeg-2.42 ± 1.04-1.80 ± 1.02-1.80 ± 0.92
Statistical analysis
  • Insulin Degludec/Liraglutide vs Insulin Degludec · ANCOVA · p = <0.0001 (p-value for superiority of IDegLira vs IDeg is presented) · Treatment contrast: -0.63 · 95% CI -0.75 to -0.52
SecondaryChange From Baseline in Fasting Plasma Glucose (FPG)

Change from baseline (week 0) in FPG after 52 weeks

Time frame:
Week 0, Week 52
Reported as:
Mean · mmol/L
Change From Baseline in Fasting Plasma Glucose (FPG)
mmol/LInsulin Degludec/LiraglutideInsulin DegludecLiraglutide
Change From Baseline in Fasting Plasma Glucose (FPG)-4.08 ± 2.47-3.97 ± 2.56-2.62 ± 1.95
SecondaryInsulin Dose

Actual daily total insulin dose after 52 weeks of treatment.

Time frame:
After 52 weeks of treatment
Reported as:
Mean · Insulin Units/Day
Insulin Dose
Insulin Units/DayInsulin Degludec/LiraglutideInsulin Degludec
Insulin Dose27.7 ± 14.834.8 ± 26.0
SecondaryResponder (Yes/no): HbA1c Less Than 7.0%

Number of subjects with HbA1c less than 7.0% after 52 weeks of treatment.

Time frame:
After 52 weeks of treatment
Reported as:
Count of participants · Participants
Responder (Yes/no): HbA1c Less Than 7.0%
ParticipantsInsulin Degludec/LiraglutideInsulin DegludecLiraglutide
Yes245189208
No308265
SecondaryResponder (Yes/no): HbA1c Less Than 7.0% and Change in Body Weight From Baseline Below or Equal to Zero

Number of subjects with HbA1c less than 7.0% and without weight gain after 52 weeks of treatment.

Time frame:
After 52 weeks of treatment
Reported as:
Count of participants · Participants
Responder (Yes/no): HbA1c Less Than 7.0% and Change in Body Weight From Baseline Below or Equal to Zero
ParticipantsInsulin Degludec/LiraglutideInsulin DegludecLiraglutide
Yes4422142
No231249131
SecondaryResponder (Yes/no): HbA1c Less Than 7.0% Without Treatment Emergent Severe or Blood Glucose (BG) Confirmed Symptomatic Hypoglycaemic Episodes During the Last 12 Weeks of Treatment.

Number of subjects with HbA1c less than 7.0% after 52 weeks, who did not experience treatment emergent severe or BG confirmed symptomatic hypoglycaemic episodes during the last 12 weeks of treatment. Treatment emergent hypoglycaemic episode is defined as an event that had onset date on or after the first day of trial product administration, and no later than 7 days after the last day on trial product. Severe or BG confirmed symptomatic hypoglycaemic episodes were defined as episodes that were severe according to the ADA classification or BG confirmed by a plasma glucose value \< 3.1 mmol/L (56 mg/dL) with symptoms consistent with hypoglycaemia.

Time frame:
After 52 weeks of treatment
Reported as:
Count of participants · Participants
Responder (Yes/no): HbA1c Less Than 7.0% Without Treatment Emergent Severe or Blood Glucose (BG) Confirmed Symptomatic Hypoglycaemic Episodes During the Last 12 Weeks of Treatment.
ParticipantsInsulin Degludec/LiraglutideInsulin DegludecLiraglutide
Yes227169206
No439665
SecondaryResponder (Yes/no): HbA1c Less Than 7.0% and Change in Body Weight From Baseline Below or Equal to Zero and Without Treatment Emergent Severe or BG Confirmed Symptomatic Hypoglycaemic Episodes During the Last 12 Weeks of Treatment

Number of subjects with HbA1c less than 7.0% and without weight gain, who did not experience treatment emergent severe or BG confirmed symptomatic hypoglycaemic episodes during the last 12 weeks of treatment. Treatment emergent hypoglycaemic episode is defined as an event that had onset date on or after the first day of trial product administration, and no later than 7 days after the last day on trial product. Severe or BG confirmed symptomatic hypoglycaemic episodes were defined as episodes that were severe according to the ADA classification or BG confirmed by a plasma glucose value \< 3.1 mmol/L (56 mg/dL) with symptoms consistent with hypoglycaemia.

Time frame:
After 52 weeks of treatment
Reported as:
Count of participants · Participants
Responder (Yes/no): HbA1c Less Than 7.0% and Change in Body Weight From Baseline Below or Equal to Zero and Without Treatment Emergent Severe or BG Confirmed Symptomatic Hypoglycaemic Episodes During the Last 12 Weeks of Treatment
ParticipantsInsulin Degludec/LiraglutideInsulin DegludecLiraglutide
Yes3722141
No233243130
SecondaryResponder (Yes/no): HbA1c Less Than 6.5%

Number of subjects with HbA1c less than 6.5% after 52 weeks of treatment.

Time frame:
After 52 weeks of treatment
Reported as:
Count of participants · Participants
Responder (Yes/no): HbA1c Less Than 6.5%
ParticipantsInsulin Degludec/LiraglutideInsulin DegludecLiraglutide
Yes213134171
No62137102
SecondaryResponder (Yes/no): HbA1c Less Than 6.5% and Change in Body Weight From Baseline Below or Equal to Zero

Number of subjects with HbA1c less than 6.5% and without weight gain after 52 weeks of treatment.

Time frame:
After 52 weeks of treatment
Reported as:
Count of participants · Participants
Responder (Yes/no): HbA1c Less Than 6.5% and Change in Body Weight From Baseline Below or Equal to Zero
ParticipantsInsulin Degludec/LiraglutideInsulin DegludecLiraglutide
Yes4117126
No234254147
SecondaryResponder (Yes/no): HbA1c Less Than 6.5% Without Treatment Emergent Severe or Blood Glucose (BG) Confirmed Symptomatic Hypoglycaemic Episodes During the Last 12 Weeks of Treatment.

Number of subjects with HbA1c less than 6.5% after 52 weeks, who did not experience treatment emergent severe or BG confirmed symptomatic hypoglycaemic episodes during the last 12 weeks of treatment. Treatment emergent hypoglycaemic episode is defined as an event that had onset date on or after the first day of trial product administration, and no later than 7 days after the last day on trial product. Severe or BG confirmed symptomatic hypoglycaemic episodes were defined as episodes that were severe according to the ADA classification or BG confirmed by a plasma glucose value \< 3.1 mmol/L (56 mg/dL) with symptoms consistent with hypoglycaemia.

Time frame:
After 52 weeks of treatment
Reported as:
Count of participants · Participants
Responder (Yes/no): HbA1c Less Than 6.5% Without Treatment Emergent Severe or Blood Glucose (BG) Confirmed Symptomatic Hypoglycaemic Episodes During the Last 12 Weeks of Treatment.
ParticipantsInsulin Degludec/LiraglutideInsulin DegludecLiraglutide
Yes198123170
No72142101
SecondaryResponder (Yes/no): HbA1c Less Than 6.5% and Change in Body Weight From Baseline Below or Equal to Zero and Without Treatment Emergent Severe or BG Confirmed Symptomatic Hypoglycaemic Episodes During the Last 12 Weeks of Treatment

Number of subjects with HbA1c less than 6.5% with no weight gain, who did not experience treatment emergent severe or BG confirmed symptomatic hypoglycaemic episodes during the last 12 weeks of treatment. Treatment emergent hypoglycaemic episode is defined as an event that had onset date on or after the first day of trial product administration, and no later than 7 days after the last day on trial product. Severe or BG confirmed symptomatic hypoglycaemic episodes were defined as episodes that were severe according to the ADA classification or BG confirmed by a plasma glucose value \< 3.1 mmol/L (56 mg/dL) with symptoms consistent with hypoglycaemia.

Time frame:
After 52 weeks of treatment
Reported as:
Count of participants · Participants
Responder (Yes/no): HbA1c Less Than 6.5% and Change in Body Weight From Baseline Below or Equal to Zero and Without Treatment Emergent Severe or BG Confirmed Symptomatic Hypoglycaemic Episodes During the Last 12 Weeks of Treatment
ParticipantsInsulin Degludec/LiraglutideInsulin DegludecLiraglutide
Yes3517125
No235248146
SecondaryChange in Waist Circumference

Change from baseline (week 0) in waist circumference after 52 weeks of treatment.

Time frame:
Week 0, Week 52
Reported as:
Mean · Cm
Change in Waist Circumference
CmInsulin Degludec/LiraglutideInsulin DegludecLiraglutide
Change in Waist Circumference2.5 ± 4.53.4 ± 5.2-1.1 ± 4.4
SecondaryChange in Blood Pressure (Systolic and Diastolic)

Change from baseline in blood pressure (systolic and diastolic) after 52 weeks of treatment.

Time frame:
Week 0, Week 52
Reported as:
Mean · mmHg
Change in Blood Pressure (Systolic and Diastolic)
mmHgInsulin Degludec/LiraglutideInsulin DegludecLiraglutide
Systolic blood pressure1.7 ± 12.03.4 ± 14.3-1.8 ± 13.0
Diastolic blood pressure0.5 ± 7.90.6 ± 9.3-0.4 ± 8.3
SecondarySelf-Measured Blood Glucose (SMBG) 9-point Profile: 9-point Profile (Individual Points in the Profile)

Subjects were instructed to measure their plasma glucose at following timepoints: before breakfast, 90 minutes after start of breakfast, before lunch, 90 minutes after start of lunch, before dinner, 90 minutes after start of dinner, at bedtime, at 4:00 a.m. and before breakfast the following day.

Time frame:
After 52 weeks of the treatment
Reported as:
Mean · mmol/L
Self-Measured Blood Glucose (SMBG) 9-point Profile: 9-point Profile (Individual Points in the Profile)
mmol/LInsulin Degludec/LiraglutideInsulin DegludecLiraglutide
Before breakfast5.90 ± 1.455.93 ± 1.647.35 ± 1.70
90 minutes after start of breakfast9.57 ± 2.8310.43 ± 3.1610.59 ± 3.25
Before lunch6.01 ± 1.906.72 ± 2.596.87 ± 2.07
90 minutes after start of lunch9.85 ± 3.1611.12 ± 3.0410.59 ± 3.38
Before dinner6.47 ± 2.446.90 ± 2.577.03 ± 2.04
90 minutes after start of dinner9.67 ± 3.0110.89 ± 3.2510.14 ± 3.03
Bedtime8.27 ± 2.799.49 ± 3.288.73 ± 2.58
At 4:00 a.m.6.12 ± 1.706.41 ± 2.187.27 ± 1.79
Before breakfast the following day5.77 ± 1.565.71 ± 1.687.13 ± 1.68
SecondaryChange in SMBG 9-point Profile - Mean of the 9-point Profile

Subjects were instructed to measure their plasma glucose at following timepoints: before breakfast, 90 minutes after start of breakfast, before lunch, 90 minutes after start of lunch, before dinner, 90 minutes after start of dinner, at bedtime, at 4:00 a.m. and before breakfast the following day. Mean of the 9-point profile was defined as the area under the profile (calculated using the trapezoidal method) divided by the measurement time.

Time frame:
Week 0, week 52
Reported as:
Mean · mmol/L
Change in SMBG 9-point Profile - Mean of the 9-point Profile
mmol/LInsulin Degludec/LiraglutideInsulin DegludecLiraglutide
Change in SMBG 9-point Profile - Mean of the 9-point Profile-4.60 ± 2.65-3.84 ± 2.63-3.46 ± 2.37
SecondaryChange in SMBG 9-point Profile - Mean of Postprandial Increments (From Before Meal to 90 Min After for Breakfast, Lunch and Dinner)

Subjects were instructed to measure their plasma glucose at following timepoints: before breakfast, 90 minutes after start of breakfast, before lunch, 90 minutes after start of lunch, before dinner, 90 minutes after start of dinner, at bedtime, at 4:00 a.m. and before breakfast the following day. The mean increment over all meals was derived as the mean of all available meal increments.

Time frame:
Week 0, week 52
Reported as:
Mean · mmol/L
Change in SMBG 9-point Profile - Mean of Postprandial Increments (From Before Meal to 90 Min After for Breakfast, Lunch and Dinner)
mmol/LInsulin Degludec/LiraglutideInsulin DegludecLiraglutide
Change in SMBG 9-point Profile - Mean of Postprandial Increments (From Before Meal to 90 Min After for Breakfast, Lunch and Dinner)-0.74 ± 2.51-0.27 ± 2.39-1.01 ± 2.38
SecondaryTotal Cholesterol as a Ratio to Baseline at 52 Weeks

Total cholesterol after 52 weeks of treatment was represented as ratio to baseline (week 0) values.

Time frame:
After 52 weeks of treatment
Reported as:
Geometric mean · Ratio
Total Cholesterol as a Ratio to Baseline at 52 Weeks
RatioInsulin Degludec/LiraglutideInsulin DegludecLiraglutide
Total Cholesterol as a Ratio to Baseline at 52 Weeks0.92 ± 13.90.97 ± 11.90.94 ± 13.0
SecondaryLow Density Lipoprotein (LDL) Cholesterol as a Ratio to Baseline at 52 Weeks

Low density lipoprotein (LDL) cholesterol after 52 weeks of treatment was represented as ratio to baseline (week 0) values.

Time frame:
After 52 weeks of treatment
Reported as:
Geometric mean · Ratio
Low Density Lipoprotein (LDL) Cholesterol as a Ratio to Baseline at 52 Weeks
RatioInsulin Degludec/LiraglutideInsulin DegludecLiraglutide
Low Density Lipoprotein (LDL) Cholesterol as a Ratio to Baseline at 52 Weeks0.91 ± 23.40.99 ± 18.20.93 ± 24.2
SecondaryHigh Density Lipoprotein (HDL) Cholesterol as a Ratio to Baseline at 52 Weeks

High density lipoprotein (HDL) cholesterol after 52 weeks of treatment was represented as ratio to baseline (week 0) values.

Time frame:
After 52 weeks of treatment
Reported as:
Geometric mean · Ratio
High Density Lipoprotein (HDL) Cholesterol as a Ratio to Baseline at 52 Weeks
RatioInsulin Degludec/LiraglutideInsulin DegludecLiraglutide
High Density Lipoprotein (HDL) Cholesterol as a Ratio to Baseline at 52 Weeks0.94 ± 16.40.94 ± 14.60.99 ± 14.5
SecondaryVery Low Density Lipoprotein (VLDL) Cholesterol as a Ratio to Baseline at 52 Weeks

Very low density lipoprotein (VLDL) cholesterol after 52 weeks of treatment was represented as ratio to baseline (week 0) values.

Time frame:
After 52 weeks of treatment
Reported as:
Geometric mean · Ratio
Very Low Density Lipoprotein (VLDL) Cholesterol as a Ratio to Baseline at 52 Weeks
RatioInsulin Degludec/LiraglutideInsulin DegludecLiraglutide
Very Low Density Lipoprotein (VLDL) Cholesterol as a Ratio to Baseline at 52 Weeks0.92 ± 44.30.97 ± 42.10.91 ± 42.2
SecondaryTriglycerides as a Ratio to Baseline at 52 Weeks

Triglycerides after 52 weeks of treatment was represented as ratio to baseline (week 0) values.

Time frame:
After 52 weeks of treatment
Reported as:
Geometric mean · Ratio
Triglycerides as a Ratio to Baseline at 52 Weeks
RatioInsulin Degludec/LiraglutideInsulin DegludecLiraglutide
Triglycerides as a Ratio to Baseline at 52 Weeks0.91 ± 48.30.96 ± 44.20.91 ± 44.0
SecondaryFree Fatty Acids as a Ratio to Baseline at 52 Weeks

Free fatty acids after 52 weeks of treatment was represented as ratio to baseline (week 0) values.

Time frame:
After 52 weeks of treatment
Reported as:
Geometric mean · Ratio
Free Fatty Acids as a Ratio to Baseline at 52 Weeks
RatioInsulin Degludec/LiraglutideInsulin DegludecLiraglutide
Free Fatty Acids as a Ratio to Baseline at 52 Weeks0.74 ± 60.80.70 ± 59.30.93 ± 49.5
SecondaryFasting C-peptide as a Ratio to Baseline at 52 Weeks

Fasting C-peptide after 52 weeks of treatment was represented as ratio to baseline (week 0) values.

Time frame:
After 52 weeks of treatment
Reported as:
Geometric mean · Ratio
Fasting C-peptide as a Ratio to Baseline at 52 Weeks
RatioInsulin Degludec/LiraglutideInsulin DegludecLiraglutide
Fasting C-peptide as a Ratio to Baseline at 52 Weeks0.61 ± 75.60.42 ± 82.61.12 ± 29.9
SecondaryFasting Human Insulin as a Ratio to Baseline at 52 Weeks

Fasting human insulin after 52 weeks of treatment was represented as ratio to baseline (week 0) values.

Time frame:
After 52 weeks of treatment
Reported as:
Geometric mean · Ratio
Fasting Human Insulin as a Ratio to Baseline at 52 Weeks
RatioInsulin Degludec/LiraglutideInsulin DegludecLiraglutide
Fasting Human Insulin as a Ratio to Baseline at 52 Weeks0.90 ± 89.00.61 ± 81.11.52 ± 66.6
SecondaryFasting Glucagon as a Ratio to Baseline at 52 Weeks

Fasting glucagon after 52 weeks of treatment was represented as ratio to baseline (week 0) values.

Time frame:
After 52 weeks of treatment
Reported as:
Geometric mean · Ratio
Fasting Glucagon as a Ratio to Baseline at 52 Weeks
RatioInsulin Degludec/LiraglutideInsulin DegludecLiraglutide
Fasting Glucagon as a Ratio to Baseline at 52 Weeks0.95 ± 27.90.94 ± 27.60.96 ± 25.7
SecondaryProinsulin as a Ratio to Baseline at 52 Weeks

Proinsulin after 52 weeks of treatment was represented as ratio to baseline (week 0) values.

Time frame:
After 52 weeks of treatment
Reported as:
Geometric mean · Ratio
Proinsulin as a Ratio to Baseline at 52 Weeks
RatioInsulin Degludec/LiraglutideInsulin DegludecLiraglutide
Proinsulin as a Ratio to Baseline at 52 Weeks0.18 ± 231.50.17 ± 188.80.59 ± 85.9
SecondaryNumber of Treatment Emergent Adverse Events (TEAEs)

Treatment emergent adverse event is defined as an event that had onset date on or after the first day of trial product administration, and no later than 7 days after the last day on trial product. If the event had onset date before the first day of exposure on randomised treatment and increased in severity during the treatment period and until 7 days after the last drug date, then this event was considered as a TEAE.

Time frame:
0-52 weeks
Reported as:
Number · Events
Number of Treatment Emergent Adverse Events (TEAEs)
EventsInsulin Degludec/LiraglutideInsulin DegludecLiraglutide
Number of Treatment Emergent Adverse Events (TEAEs)873829885
SecondaryNumber of Treatment Emergent Severe or Blood Glucose (BG) Confirmed Symptomatic Hypoglycaemic Episodes

Treatment emergent hypoglycaemic episode is defined as an event that had onset date on or after the first day of trial product administration, and no later than 7 days after the last day on trial product. Severe or BG confirmed symptomatic hypoglycaemic episodes were defined as episodes that were severe according to the American Diabetes Association (ADA) classification or BG confirmed by a plasma glucose value \< 3.1 mmol/L (56 mg/dL) with symptoms consistent with hypoglycaemia. Severe hypoglycaemia according to the ADA definition: an episode requiring assistance of another person to actively administer carbohydrate, glucagon, or take other corrective actions. Plasma glucose concentrations may not be available during an event, but neurological recovery following the return of plasma glucose to normal is considered sufficient evidence that the event was induced by a low plasma glucose concentration.

Time frame:
0-52 weeks
Reported as:
Number · Episodes
Number of Treatment Emergent Severe or Blood Glucose (BG) Confirmed Symptomatic Hypoglycaemic Episodes
EpisodesInsulin Degludec/LiraglutideInsulin DegludecLiraglutide
Number of Treatment Emergent Severe or Blood Glucose (BG) Confirmed Symptomatic Hypoglycaemic Episodes135362136
SecondaryNumber of Treatment Emergent Nocturnal Severe or BG Confirmed Symptomatic Hypoglycaemic Episodes

Treatment emergent hypoglycaemic episode is defined as an event that had onset date on or after the first day of trial product administration, and no later than 7 days after the last day on trial product. Nocturnal period: The period between 00:01 and 05:59 a.m. (both inclusive). Severe or BG confirmed symptomatic hypoglycaemic episodes were defined as episodes that were severe according to the American Diabetes Association (ADA) classification or BG confirmed by a plasma glucose value \< 3.1 mmol/L (56 mg/dL) with symptoms consistent with hypoglycaemia. Severe hypoglycaemia according to the ADA definition: an episode requiring assistance of another person to actively administer carbohydrate, glucagon, or take other corrective actions. Plasma glucose concentrations may not be available during an event, but neurological recovery following the return of plasma glucose to normal is considered sufficient evidence that the event was induced by a low plasma glucose concentration.

Time frame:
0-52 weeks
Reported as:
Number · Episodes
Number of Treatment Emergent Nocturnal Severe or BG Confirmed Symptomatic Hypoglycaemic Episodes
EpisodesInsulin Degludec/LiraglutideInsulin DegludecLiraglutide
Number of Treatment Emergent Nocturnal Severe or BG Confirmed Symptomatic Hypoglycaemic Episodes16420
SecondaryNumber of Treatment Emergent Hypoglycaemic Episodes According to American Diabetes Association (ADA) Definition

Results represent total number of treatment emergent hypoglycaemic episodes that fall under ADA's definition of hypoglycaemia. ADA's definition of hypoglycaemia includes following categories: 1. Severe hypoglycaemia 2. Documented symptomatic hypoglycaemia 3. Asymptomatic hypoglycaemia 4. Probable symptomatic hypoglycaemia 5. Pseudo-hypoglycaemia. Treatment emergent hypoglycaemic episode is defined as an event that had onset date on or after the first day of trial product administration, and no later than 7 days after the last day on trial product.

Time frame:
0-52 weeks
Reported as:
Number · Episodes
Number of Treatment Emergent Hypoglycaemic Episodes According to American Diabetes Association (ADA) Definition
EpisodesInsulin Degludec/LiraglutideInsulin DegludecLiraglutide
Number of Treatment Emergent Hypoglycaemic Episodes According to American Diabetes Association (ADA) Definition48306340162
SecondaryAnti-drug Antibodies: Anti-insulin Degludec Antibodies

Insulin degludec (IDeg)-specific antibodies were measured at week 52, as %B/T (percentage of bound \& precipitated radioactive drug/total added drug to the sample). A sample is measured in 2 different series. In series 1, the radioactive IDeg (tracer) and surplus unlabeled IDeg are added to the sample. In series 2, the tracer and surplus unlabeled human insulin are added to the sample. Series 1 represents unspecific background binding. Series 2 represents IDeg specific antibodies including unspecific background binding. The reported %B/T is calculated by subtracting the background %B/T in series 1 from the %B/T result in series 2. If the background result has higher values than the %B/T in series 2, the resulting value is negative %B/T. Here, a negative %B/T value means that the test samples do not have IDeg-specific antibodies. The reason for getting a negative value for %B/T is due to variation in the analytical background. Thus, the results presented are not a change from baseline.

Time frame:
at week 52
Reported as:
Mean · Percentage B/T
Anti-drug Antibodies: Anti-insulin Degludec Antibodies
Percentage B/TInsulin Degludec/LiraglutideInsulin Degludec
Anti-drug Antibodies: Anti-insulin Degludec Antibodies0.12 ± 3.34-0.11 ± 0.42
SecondaryAnti-drug Antibodies: Number of Participants Positive or Negative for Anti-liraglutide Antibodies

Anti-liraglutide antibodies were measured at week 52. Number of participants positive or negative for anti-liraglutide antibodies at week 52 were reported.

Time frame:
at week 52
Reported as:
Count of participants · Participants
Anti-drug Antibodies: Number of Participants Positive or Negative for Anti-liraglutide Antibodies
ParticipantsInsulin Degludec/LiraglutideLiraglutide
Negative247224
Positive2849
SecondaryChange in Clinical Evaluation: Fundoscopy or Fundus Photography

The result of the fundus photography/dilated fundoscopy was interpreted by the investigator into following categories: Normal; Abnormal (Abn), Not Clinically significant (NCS); Abnormal, Clinically significant (CS). Reported results are number of subjects with 'normal'; 'Abn, NCS' and 'Abn, CS' fundoscopy/fundus photography results at screening (week -2 to week 0) and week 52.

Time frame:
at screening (week -2 to week 0), at week 52
Reported as:
Count of participants · Participants
Change in Clinical Evaluation: Fundoscopy or Fundus Photography
ParticipantsInsulin Degludec/LiraglutideInsulin DegludecLiraglutide
Left eye - at screening visit - normal225213211
Left eye - at screening visit - Abn, NCS101614
Left eye - at screening visit - Abn, CS394247
Left eye - week 52 - normal217214212
Left eye - week 52 - Abn, NCS171615
Left eye - week 52 - Abn, CS404145
Right eye - at screening visit - normal224212207
Right eye - at screening visit - Abn, NCS101412
Right eye - at screening visit - Abn, CS414554
Right eye - week 52 - normal220217209
Right eye - week 52 - Abn, NCS141415
Right eye - week 52 - Abn, CS414049
SecondaryChange in Clinical Evaluation: Electrocardiogram (ECG)

The result of the ECG was interpreted by the investigator into following categories: Normal; Abnormal (Abn), Not Clinically significant (NCS); Abnormal, Clinically significant (CS). Reported results are number of subjects with 'normal'; 'Abn, NCS' and 'Abn, CS' ECG results at screening (week -2 to week 0) and week 52.

Time frame:
at screening (week -2 to week 0), at week 52
Reported as:
Count of participants · Participants
Change in Clinical Evaluation: Electrocardiogram (ECG)
ParticipantsInsulin Degludec/LiraglutideInsulin DegludecLiraglutide
At screening visit - normal228230222
At screening visit - Abn, NCS403841
At screening visit - Abn, CS7310
Week 52 - normal238232233
Week 52 - Abn, NCS303534
Week 52 - Abn, CS746
SecondaryChange in Clinical Evaluation: Pulse

Change in pulse after 52 weeks of treatment.

Time frame:
Week 0, week 52
Reported as:
Mean · beats per minute
Change in Clinical Evaluation: Pulse
beats per minuteInsulin Degludec/LiraglutideInsulin DegludecLiraglutide
Change in Clinical Evaluation: Pulse3.9 ± 9.50.8 ± 8.94.2 ± 9.1
SecondarySerum Concentrations of Insulin Degludec

Samples from the IDegLira and IDeg arms were analysed for serum concentrations of insulin degludec using validated ELISA assays.

Time frame:
Weeks 2, 8, 16, 26, 44, 52
Reported as:
Geometric mean · pmol/L
Serum Concentrations of Insulin Degludec
pmol/LInsulin Degludec/LiraglutideInsulin Degludec
At week 21468.7 ± 55.91477.1 ± 61.3
At week 82246.0 ± 72.22524.6 ± 71.5
At week 162511.0 ± 83.62856.4 ± 84.4
At week 262597.3 ± 88.32946.9 ± 91.1
At week 442766.6 ± 85.83238.8 ± 91.7
At week 522393.8 ± 116.73124.4 ± 101.2
SecondaryPlasma Concentrations of Liraglutide

Samples from the IDegLira and liraglutide arms were assayed for plasma concentrations of liraglutide using validated ELISA assays.

Time frame:
Weeks 2, 8, 16, 26, 44, 52
Reported as:
Geometric mean · pmol/L
Plasma Concentrations of Liraglutide
pmol/LInsulin Degludec/LiraglutideLiraglutide
At week 25681.3 ± 49.46081.6 ± 65.4
At week 89107.8 ± 61.414539.5 ± 71.0
At week 1610038.1 ± 69.514046.5 ± 73.0
At week 269995.3 ± 77.513904.2 ± 91.8
At week 448791.7 ± 81.012855.6 ± 112.7
At week 527426.2 ± 103.512127.4 ± 142.4

Adverse events

Collected over Week 0 (randomisation) to week 52 (end of treatment) and 7 days after end of treatment.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Insulin Degludec/Liraglutide1/275 (0.4%)17/275 (6.2%)153/275 (55.6%)
Insulin Degludec0/271 (0%)13/271 (4.8%)137/271 (50.6%)
Liraglutide0/273 (0%)14/273 (5.1%)158/273 (57.9%)
Most frequent serious events
Showing 10 of 45
Most frequent serious events
EventInsulin Degludec/LiraglutideInsulin DegludecLiraglutide
Angina pectorisCardiac disorders2/2750/2710/273
Acute myocardial infarctionCardiac disorders0/2751/2710/273
Adrenal neoplasmNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/2751/2710/273
Atrioventricular block completeCardiac disorders0/2751/2710/273
Carpal tunnel syndromeNervous system disorders0/2751/2710/273
Endometrial hyperplasiaReproductive system and breast disorders0/2751/2710/273
Herpes zoster meningitisInfections and infestations0/2751/2710/273
Hypoglycaemic unconsciousnessNervous system disorders0/2751/2710/273
Lung adenocarcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/2751/2710/273
Lung neoplasm malignantNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/2751/2710/273
Most frequent other events
Showing 10 of 11
Most frequent other events
EventInsulin Degludec/LiraglutideInsulin DegludecLiraglutide
Viral upper respiratory tract infectionInfections and infestations106/27591/27194/273
ConstipationGastrointestinal disorders27/27512/27138/273
DiarrhoeaGastrointestinal disorders15/27512/27124/273
NauseaGastrointestinal disorders9/2755/27123/273
Weight increasedInvestigations4/27519/2711/273
Diabetic retinopathyEye disorders17/27512/27111/273
EczemaSkin and subcutaneous tissue disorders16/2756/2719/273
PharyngitisInfections and infestations11/27515/2719/273
HeadacheNervous system disorders7/2757/27115/273
Lipase increasedInvestigations6/2750/27115/273

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Insulin Degludec/LiraglutideInsulin DegludecLiraglutideTotal
Mean56.9 ± 10.257.8 ± 9.956.8 ± 10.157.2 ± 10.1
Sex: Female, Male
Sex: Female, Male(Participants)Insulin Degludec/LiraglutideInsulin DegludecLiraglutideTotal
Female817681238
Male194195192581
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Insulin Degludec/LiraglutideInsulin DegludecLiraglutideTotal
Hispanic or Latino0000
Not Hispanic or Latino0000
Unknown or Not Reported275271273819
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Insulin Degludec/LiraglutideInsulin DegludecLiraglutideTotal
American Indian or Alaska Native0000
Asian275271273819
Native Hawaiian or Other Pacific Islander0000
Black or African American0000
White0000
More than one race0000
Unknown or Not Reported0000
Glycosylated Haemoglobin (HbA1c)
Glycosylated Haemoglobin (HbA1c)(Percentage of HbA1c)Insulin Degludec/LiraglutideInsulin DegludecLiraglutideTotal
Mean8.52 ± 1.128.53 ± 1.058.32 ± 0.998.45 ± 1.06
09

Study locations

76 sites
  • Novo Nordisk Investigational Site
    Adachi-ku, Tokyo, 123-0845, Japan
  • Novo Nordisk Investigational Site
    Akita-shi, Akita, 010-8543, Japan
  • Novo Nordisk Investigational Site
    Annaka-shi, Gunma, 379-0116, Japan
  • Novo Nordisk Investigational Site
    Asahikawa-shi, Hokkaido, 070-0002, Japan
  • Novo Nordisk Investigational Site
    Chiba-shi, Chiba, 260-0804, Japan
  • Novo Nordisk Investigational Site
    Chitose, Hokkaido, 066-0032, Japan
  • Novo Nordisk Investigational Site
    Chuo-ku, Tokyo, 103-0002, Japan
  • Novo Nordisk Investigational Site
    Chuo-ku,Tokyo, 103-0025, Japan
  • Novo Nordisk Investigational Site
    Chuo-ku,, 104 0061, Japan
  • Novo Nordisk Investigational Site
    Edogawa-ku, Tokyo, 134-0084, Japan
  • Novo Nordisk Investigational Site
    Fujisawa-shi, Kanagawa, 251-0041, Japan
  • Novo Nordisk Investigational Site
    Fukuoka-shi, Fukuoka, 819-0168, Japan
  • Novo Nordisk Investigational Site
    Fukushima, 963-8851, Japan
  • Novo Nordisk Investigational Site
    Gunma, 373-0036, Japan
  • Novo Nordisk Investigational Site
    Hachioji-shi, Tokyo, 192-0917, Japan
  • Novo Nordisk Investigational Site
    Hokkaido, 060-0062, Japan
  • Novo Nordisk Investigational Site
    Hokkaido, 078-8236, Japan
  • Novo Nordisk Investigational Site
    Ibaraki, 311-0113, Japan
  • Novo Nordisk Investigational Site
    Ichihara-shi, Chiba, 290-0003, Japan
  • Novo Nordisk Investigational Site
    Iruma-shi, Saitama, 358-0011, Japan
  • Novo Nordisk Investigational Site
    Itabashi-ku, Tokyo, 173-0004, Japan
  • Novo Nordisk Investigational Site
    Itabashi-ku, Tokyo, 175-0093, Japan
  • Novo Nordisk Investigational Site
    Izumisano-shi,Osaka, 598-8577, Japan
  • Novo Nordisk Investigational Site
    Izumisano-shi, 598 0048, Japan
  • Novo Nordisk Investigational Site
    Kagoshima-shi, Kagoshima, 890-0061, Japan
  • Novo Nordisk Investigational Site
    Kamakura-shi, 247 0056, Japan
  • Novo Nordisk Investigational Site
    Kanagawa, 235-0045, Japan
  • Novo Nordisk Investigational Site
    Kanra-gun, Gunma, 370-2214, Japan
  • Novo Nordisk Investigational Site
    Kashiwara-shi, Osaka, 582-0005, Japan
  • Novo Nordisk Investigational Site
    Kawagoe-shi, Saitama, 350-0851, Japan
  • Novo Nordisk Investigational Site
    Kawaguchi-shi, Saitama, 332-0012, Japan
  • Novo Nordisk Investigational Site
    Kawasaki-shi,Kanagawa, 215-0026, Japan
  • Novo Nordisk Investigational Site
    Kisarazu-shi, Chiba, 292-0038, Japan
  • Novo Nordisk Investigational Site
    Kobe-shi, Hyogo, Japan
  • Novo Nordisk Investigational Site
    Kuki-shi, Saitama, 346-8530, Japan
  • Novo Nordisk Investigational Site
    Kumamoto-shi, Kumamoto, 860-0811, Japan
  • Novo Nordisk Investigational Site
    Kumamoto-shi, Kumamoto, 861-8039, Japan
  • Novo Nordisk Investigational Site
    Kumamoto, 862-0976, Japan
  • Novo Nordisk Investigational Site
    Kushiro-shi, Hokkaido, 085-0032, Japan
  • Novo Nordisk Investigational Site
    Kyoto-shi, Kyoto, 606-8507, Japan
  • Novo Nordisk Investigational Site
    Minato-ku, Tokyo, 108-0075, Japan
  • Novo Nordisk Investigational Site
    Mito-shi, Ibaraki, 310-0826, Japan
  • Novo Nordisk Investigational Site
    Mito-shi, Ibaraki, 311-4153, Japan
  • Novo Nordisk Investigational Site
    Miura-shi, Kanagawa, 238-0101, Japan
  • Novo Nordisk Investigational Site
    Miyazaki, 880-0034, Japan
  • Novo Nordisk Investigational Site
    Nagoya-shi, Aichi, 455-8530, Japan
  • Novo Nordisk Investigational Site
    Nagoya-shi, Aichi, 456-0058, Japan
  • Novo Nordisk Investigational Site
    Nishinomiya-shi, Hygo, 662 0971, Japan
  • Novo Nordisk Investigational Site
    Obihiro-shi, Hokkaido, 080 0016, Japan
  • Novo Nordisk Investigational Site
    Obihiro-shi, Hokkaido, 080 0848, Japan
  • Novo Nordisk Investigational Site
    Oita-shi, 870 0039, Japan
  • Novo Nordisk Investigational Site
    Okawa-shi, Fukuoka, 831-0016, Japan
  • Novo Nordisk Investigational Site
    Onga-gun, Fukuoka, 811-4342, Japan
  • Novo Nordisk Investigational Site
    Osaka-shi, Osaka, 530-0013, Japan
  • Novo Nordisk Investigational Site
    Osaka-shi, Osaka, 533-0024, Japan
  • Novo Nordisk Investigational Site
    Osaka-shi, Osaka, 536-0001, Japan
  • Novo Nordisk Investigational Site
    Osaka, 569-1045, Japan
  • Novo Nordisk Investigational Site
    Ota-ku, Tokyo, 1430015, Japan
  • Novo Nordisk Investigational Site
    Saijo-shi, Ehime, 793-0027, Japan
  • Novo Nordisk Investigational Site
    Sapporo-shi, Hokkaido, 004-0004, Japan
  • Novo Nordisk Investigational Site
    Sapporo-shi, Hokkaido, 060-0001, Japan
  • Novo Nordisk Investigational Site
    Sendai-shi, Miyagi, 980-0011, Japan
  • Novo Nordisk Investigational Site
    Sendai-shi, Miyagi, 980-0021, Japan
  • Novo Nordisk Investigational Site
    Shimotsuke-shi, Tochigi, 329-0433, Japan
  • Novo Nordisk Investigational Site
    Shizuoka-shi, Shizuoka, 424-0853, Japan
  • Novo Nordisk Investigational Site
    Tochigi, 323-0022, Japan
  • Novo Nordisk Investigational Site
    Tokyo, 103-0027, Japan
  • Novo Nordisk Investigational Site
    Tokyo, 103-0028, Japan
  • Novo Nordisk Investigational Site
    Tokyo, 104-0031, Japan
  • Novo Nordisk Investigational Site
    Tokyo, 169-0073, Japan
  • Novo Nordisk Investigational Site
    Toshima-ku, Tokyo, 171-0021, Japan
  • Novo Nordisk Investigational Site
    Toyonaka-shi, Osaka, 560-0082, Japan
  • Novo Nordisk Investigational Site
    Ube-shi, Yamaguchi, 755-0046, Japan
  • Novo Nordisk Investigational Site
    Urasoe-shi,, 901 2104, Japan
  • Novo Nordisk Investigational Site
    Yamaguchi-shi, Yamaguchi, 754-0002, Japan
  • Novo Nordisk Investigational Site
    Yamato-shi, Kanagawa, 242-0004, Japan
10

References and documents

Publications

  • Kaku K, Araki E, Tanizawa Y, Ross Agner B, Nishida T, Ranthe M, Inagaki N. Superior efficacy with a fixed-ratio combination of insulin degludec and liraglutide (IDegLira) compared with insulin degludec and liraglutide in insulin-naive Japanese patients with type 2 diabetes in a phase 3, open-label, randomized trial. Diabetes Obes Metab. 2019 Dec;21(12):2674-2683. doi: 10.1111/dom.13856. Epub 2019 Aug 28. PubMed 31407845 ↗
  • Komatsu M, Watada H, Kaneko S, Ross Agner BF, Nishida T, Kaku K. Efficacy and safety of the fixed-ratio combination of insulin degludec and liraglutide by baseline glycated hemoglobin, body mass index and age in Japanese individuals with type 2 diabetes: A subgroup analysis of two phase III trials. J Diabetes Investig. 2021 Sep;12(9):1610-1618. doi: 10.1111/jdi.13525. Epub 2021 Mar 24. PubMed 33595901 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — According to the Novo Nordisk disclosure commitment on novonordisk-trials.com

11

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2015 to primary completion in Dec 2017, 24 months.

Results were first posted in Jul 2019, 1 year 7 months after primary completion.

Of 438 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 26. This study's 24 months is above that.

Counting every sponsor, half of 525 studies reached it within 20 months; a quarter within 14 and three quarters within 30.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 16, 2015
First posted
Nov 18, 2015
StartActual
Nov 18, 2015
Primary completionActual
Dec 15, 2017
CompletionActual
Dec 22, 2017
Results first posted
Jul 29, 2019
Last update
Apr 9, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 9, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
12

Registry details

Key details

Study ID
NCT02607306
Lead sponsor
Novo Nordisk A/S
Responsible party
Sponsor
First posted
Nov 18, 2015
Start date
Nov 18, 2015
Primary completion
Dec 15, 2017
Completion
Dec 22, 2017
Results posted
Jul 29, 2019
Last update
Apr 9, 2021

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Insulin degludec · Liraglutide

Start the discussion